BioCryst Pharmaceuticals (BCRX) Cantor Global Healthcare Conference 2025 summary

Business highlights and strategic outlook

• ORLADEYO is projected to reach $580–$600 million in global sales this year, growing at a 20% CAGR, with expectations to peak at $1 billion by decade's end and maintain strong patent protection until 2039.

• The European business is being sold for $250 million, improving the balance sheet and enabling a focus on the more profitable U.S. market and future strategic options.

• Management transition is underway, with a new CEO starting in January and a strengthened focus on leveraging commercial infrastructure for future product launches.

• The company is actively seeking late-stage rare disease assets, especially in allergy, immunology, and rare dermatology, to complement its internal pipeline and drive growth.

• Financing options for acquisitions are broad, including cash, debt, synthetic royalties, and stock, supported by improved profitability and cash flow post-divestiture.

Product and pipeline developments

• ORLADEYO remains differentiated as the only oral, once-daily prophylactic therapy for HAE, with new competition seen as an opportunity to attract more patients.

• Pediatric indication for ORLADEYO granules is pending, with a PDUFA date in December, potentially expanding the addressable market to children aged 2–12.

• Real-world evidence and monthly patient data collection support prescriber confidence and product positioning.

• Pipeline includes BCX7725 for Netherton syndrome, with initial patient data expected by year-end, and Avoralstat for DME, targeting a 50–70 micron reduction in retinal thickness in early studies.

• Regulatory path for Netherton syndrome is being defined, with potential for a small pivotal study if early efficacy is strong.

Market dynamics and competitive landscape

• New injectable competitors in HAE are not expected to significantly impact ORLADEYO's growth due to its oral administration advantage.

• The emergence of oral on-demand therapies may provide a tailwind by enabling an all-oral treatment regimen for patients.

• Net pricing remains stable, with gross-to-net at about 15% off list price and strong payer acceptance due to a growing patient base.

• The company is positioned as a consolidator in rare diseases, leveraging its commercial and operational infrastructure to integrate new assets efficiently.

• Current market conditions favor buyers, with high willingness among both public and private companies to engage in asset sales or partnerships.